


RESEARCH

Open Access



Expression of the human molecular chaperone domain Bri2 BRICHOS on a gram per liter scale with an *E. coli* fed-batch culture

Benjamin Schmuck^{1,2*} , Gefei Chen¹, Josef Pelcman¹, Nina Kronqvist¹, Anna Rising^{1,2} and Jan Johansson¹

Abstract

Background: The human Bri2 BRICHOS domain inhibits amyloid formation and toxicity and could be used as a therapeutic agent against amyloid diseases. For translation into clinical use, large quantities of correctly folded recombinant human (rh) Bri2 BRICHOS are required. To increase the expression and solubility levels of rh Bri2 BRICHOS it was fused to NT*, a solubility tag derived from the N-terminal domain of a spider silk protein, which significantly increases expression levels and solubility of target proteins. To increase the expression levels even further and reach the g/L range, which is a prerequisite for an economical production on an industrial scale, we developed a fed-batch expression protocol for *Escherichia coli*.

Results: A fed-batch production method for NT*-Bri2 BRICHOS was set up and systematically optimized. This gradual improvement resulted in expression levels of up to 18.8 g/L. Following expression, NT*-Bri2 BRICHOS was purified by chromatographic methods to a final yield of up to 6.5 g/L. After removal of the NT*-tag and separation into different oligomeric species, activity assays verified that different assembly states of the fed-batch produced rh Bri2 BRICHOS have the same ability to inhibit fibrillar and non-fibrillar protein aggregation as the reference protein isolated from shake flask cultures.

Conclusions: The protocol developed in this work allows the production of large quantities of rh Bri2 BRICHOS using the solubility enhancing NT*-tag as a fusion partner, which is required to effectively conduct pre-clinical research.

Keywords: Solubility tag, Bioreactor, High cell density culture, Protein expression, Protein purification

Background

Alzheimer's disease (AD) is the most common cause of dementia and belongs to a group of diseases that are characterized by the formation of deposits of specific proteins in amyloid fibrillar conformations [1]. Despite immense efforts from academia and the pharmaceutical industry, no disease-modifying treatment has been developed so far [2]. This is not only a problem for the patients and their families but also threatens to undermine the

health care system at large since the progressive neurodegenerative nature of AD inevitably results in long-standing, severe decline in mental and physical status, and patients eventually require full-time attention [3]. This situation makes it necessary to investigate novel approaches to treat AD.

A large proportion of the human proteome has been found to contain amyloidogenic sequence motifs [4], suggesting that there are specific endogenous mechanisms that protect amyloidogenic proteins from forming amyloid that otherwise would cause disease. The BRICHOS domain (named from its discovery in Bri2, chondromodulin-1, and progranulin C) has emerged as the first example of an endogenous molecular chaperone-like

*Correspondence: benjamin.schmuck@ki.se

¹ Department of Biosciences and Nutrition, Karolinska Institutet, Neo, 141 86 Huddinge, Sweden

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

domain that protects amyloidogenic protein segments from forming amyloid [5, 6]. The BRICHOS domains from different proteins can also prevent other amyloidogenic proteins than their natural targets from forming amyloid, and this raised the possibility to harness BRICHOS as a therapeutic strategy against amyloid diseases such as AD [7].

Mutations in the BRICHOS containing protein Bri2, which is associated with familial British and Danish dementias, give rise to the extended amyloidogenic peptides ABri and ADan, respectively [8, 9]. Bri2 BRICHOS can prevent amyloid formation also of non-client peptides, including amyloid β peptide ($A\beta$) and islet amyloid polypeptide (IAPP), associated with AD and type 2 diabetes, respectively [10, 11]. For instance, Bri2 BRICHOS prevents amyloid formation and neurotoxicity of the 42-residue $A\beta$ 42, the main amyloidogenic species in AD, in transgenic fruit flies and mice and prevents $A\beta$ 42 neurotoxicity in mouse hippocampal slices in vitro [12–15]. Moreover, recombinant human (rh) Bri2 BRICHOS passes the blood-brain barrier in wild-type mice, making parenteral administration of rh Bri2 BRICHOS an interesting new potential treatment against AD [16, 17]. Such application of rh Bri2 BRICHOS would require industrial protein production and purification protocols that result in a homogenous product at a reasonable cost.

Rh BRICHOS can be produced on a laboratory scale using strategies involving the use of fusion partners [18]. However, it was found that rh Bri2 BRICHOS forms different assembly states, primarily monomers, dimers, and high molecular weight oligomers consisting of about 20–30 subunits, which are difficult to resolve [15]. To circumvent this problem, we used a new production strategy that stems from insights into the silk production process of spiders.

Spider silk proteins (spidroins) are aggregation prone and have been found to form amyloid-like fibrils, making their production and storage at very high concentrations until silk formation takes place a formidable challenge [19]. The spidroin N-terminal domain (NT) works as a solubility enhancer that enables the storage of spidroins and prevents precocious aggregation [20]. This function can be harnessed also for improved solubility and the production of non-spidroins. In particular, a designed mutant, NT*, can keep very aggregation-prone proteins, including amyloid forming proteins, proteases, and membrane proteins, in solution [21–24]. NTs from widely different spidroins and spider species share the ability to improve solubility and increase recombinant production yields of aggregation prone proteins [23]. NT*, derived from the major ampullate spidroin from *Euprosthenops australis* spiders, was recently used as a tag to produce rh Bri2 BRICHOS and this enabled successful separation of

the different assembly states [25]. Herein we investigate the feasibility to use *Escherichia coli* (*E. coli*) to produce NT*-Bri2 BRICHOS in bioreactors and study how the released target protein Bri2 BRICHOS acts as an inhibitor of fibrillar and non-fibrillar protein aggregation.

Materials and methods

Expression of NT*-Bri2 BRICHOS in *E. coli* bioreactor cultivations

A single colony of SHuffle T7 *E. coli* (New England Biolabs, Ipswich, USA) transformed with a pET-based plasmid encoding the gene for NT*-Bri2 BRICHOS [25] was used to inoculate 20 mL LB-medium (containing 50 mg/L kanamycin and 1% glycerol). The culture was incubated at 30 °C and 220 rpm in a baffled flask overnight. Then, the culture was diluted 50 to 100 times into fresh medium to obtain an OD_{600} of 0.05. In total 11 bioreactor cultivations were carried out in a Multifors 2 (Infors HT Basel, Switzerland) (Culture #1 to #5) or Minifors 2 (Infors HT, Basel, Switzerland) (Culture #6 to #11) with culture sizes in the range between 250–400 or 900–1200 mL, respectively. The pH of all cultures was continuously adjusted to 7, by the addition of either 3 M H_3PO_4 or 25% NH_3 . The oxygenation level, pO_2 was set to 30%, which was achieved by increasing the stirrer speed and/or the air-flow rate. All cultivation media described hereafter were adopted from earlier reported recipes and were prepared by first autoclaving the main components in the reaction vessel, followed by separate addition of sterile stock solutions of filtered glucose (700 g/L) and kanamycin (30 g/L), as well as autoclaved antifoam 204 (10%, Sigma Aldrich), trace metal solution (25 \times), and $MgSO_4$ (500 g/L), where applicable. The kanamycin concentration was 30 mg/L in all cultivations, and the initial concentration of antifoam 204 was 0.01%.

In cultures #1 & 2, the expression of NT*-Bri2 BRICHOS using complex media formulations including Lysogeny Broth (LB) and Terrific Broth (TB) were tested. These were grown continuously at 30 °C in a batch manner and were induced by adding IPTG to 500 μ M when OD_{600} was still below 1. As a next step, the expression levels of NT*-Bri2 BRICHOS in semi-defined and defined media according to da Silva [26] (Batch medium adapted from experiment #4, feed medium from experiment #3 without lactose), Korz [27], and Wyre [28] (semi-defined medium described in the paper) was tested (culture # 3–5). After growing the cultures to $OD_{600} \approx 30$ (da Silva and Wyre) or 13 (Korz), they were induced by the addition of 33 μ M IPTG. During the entire cultivation time, the temperature was held constant at 25 °C. In the next cultivation series, the medium formulation suggested by da Silva was used to identify the most optimal IPTG concentration to maximize the yield of soluble rh NT*-Bri2

BRICHOS. In this experiment, cultures #6–8 were grown at a constant temperature of 25 °C and induced with 50, 150, or 500 μM IPTG once OD₆₀₀ reached ≈ 30 (≈1 L sized cultivations). Culture #9-11 is a replication of culture #7 (induction with 150 μM IPTG), with the exception that induction was implemented once OD₆₀₀ reached 60. Furthermore, ~3 h before induction the temperature was carefully increased to 27 °C, to enable faster growth, and then reduced to 25 °C when the cultures were induced with IPTG:

Independent of the induction point, exponential feeding was initialized in all experiments once pO₂ levels increased suddenly, indicating that the carbon source contained in the batch medium was depleted. The feeding rate was adjusted to an exponential feeding profile according to Eq. (1) [29]:

$$F = \frac{1}{S} * \left(\frac{\mu}{Y_{X/S}} + m \right) * X_0 * e^{\mu t} \quad (1)$$

where F is the rate of feeding (L h⁻¹), s the concentration of the glycerol/glucose in the feed (g L⁻¹), μ the specific growth rate (h⁻¹), $Y_{X/S}$ the biomass yield on the substrate (g g⁻¹), m the specific maintenance coefficient (g g⁻¹ h⁻¹), X the biomass concentration (g L⁻¹). The specific growth rate μ was set to 0.1, m to 0.025 g g⁻¹ h⁻¹,

and $Y_{X/S}$ was 0.622 g g⁻¹ [26]. A summary of all essential cultivation parameters is found in Table 1.

After cultivation, the cells were harvested in a Sorvall LYNX 6000 (Thermo Scientific) centrifuge, using an F9-6 × 1000 LEX rotor at 4000× g for 20 min. Then, the cell pellet was re-suspended by gentle agitation at 4 °C in Buffer A (20 mM tris, pH 8.0), using 20 mL buffer per 10 g wet cell weight. Cell resuspensions were stored at -20 °C.

Purification using immobilized metal ion affinity chromatography (IMAC)

A 50 mL cell resuspension was thawed and lysed using a cell disruptor (Constant Systems, Daventry, United Kingdom) at 1.35 kbar. Then DNase I (Roche, Basel, Switzerland) was added to the lysed cells to a final concentration of 10 μg/mL, followed by incubation on ice for 30 min, and by centrifugation at 38,000× g in a Sorvall RC 6+ (Thermo Fisher Scientific) using an F21-8 × 50y rotor (4 °C for 30 min). After centrifugation, the supernatant was filtered through a Filtrapor S 0.45 (Sarstedt, Nümbrecht, Germany). All subsequent purification steps were carried out on an Äkta Explorer liquid chromatographic system (GE Healthcare, Uppsala, Sweden) at 6 °C. The lysate was loaded onto 4 × 5 mL HiTrap Chelating HP columns

Table 1 Summary of key parameters for the expression and purification of NT*Bri2 BRICHOS expressed in bioreactor cultivations in this study

Culture	#1	#2	#3	#4	#5	#6	#7	#8	#9 ^d
Temperature (°C)	30	30	25	25	25	25	25	25	25
Medium	LB	TB	da Silva	Korz	Wyre	da Silva	da Silva	da Silva	da Silva
Substrate in feed			Glycerol	Glycerol	Glycerol	Glycerol	Glycerol	Glycerol	Glycerol
IPTG (μM)	500	500	33	33	33	50	150	500	150
OD ₆₀₀ induced	1	0.6	30	13	35	32	25	29	60
OD ₆₀₀ harvest	8.4	31	121	50	61	190	106	76	176
Induction time (h)	21	21	15	10	10	20	20	20	22
Total culture time (h)	26	26	39	39	39	47	47	47	49
Culture Size (mL)	400	400	325	274	307	910	900	907	1180
Wet Cell Weight (g/L)	13	32	197	58	81	200	120	82	214 ^e
Expression level (g/L) ^a	0.53	0.82	2.1	2.1	2.7	7.9	7.9	6.2	18.8 ^f
% of culture purified	100%	100%	25%	100%	50%	9.1%	11.6%	25%	7.1%
Purified (mg) ^b	37	73	40	70	92	133	428	510	540
Yield after purification (g/L) ^c	0.09	0.18	0.49	0.26	0.60	1.61	4.12	2.25	6.41
% of expression level	17.6%	22.3%	23.8%	11.9%	22.1%	20.4%	51.8%	36.4%	34.1%

^a Expression level of NT*Bri2 BRICHOS was estimated with SDS-PAGE. See also Additional file 1: Figures S2, S3

^b Protein yield was calculated using Abs₂₈₀ and the protein specific extinction coefficient after NT*Bri2 BRICHOS was eluted and dialyzed to remove imidazole

^c Yield of NT*Bri2 BRICHOS after purification

^d Culture #9 was repeated 2 more times to estimate the batch-to-batch variation see Additional file 1: Table S1

^e Dry cell weight for culture #9 was 82 g/L

^f The expression level calculated by considering the % of NT*Bri2 BRICHOS relative to the total protein content and the dry cell mass is 15.2 g/L

(GE Healthcare, Uppsala, Sweden) equilibrated with buffer A using a flow rate of 2.5 mL/min. Next, the proteins bound to the column were washed with buffer A containing 40 mM imidazole, before NT*-Bri2 BRICHOS was eluted with buffer A containing 200 mM imidazole. After elution, the flow-through was re-applied onto the columns, and NT*-Bri2 BRICHOS was washed and eluted in the same manner one more time. The combined eluate was subsequently dialyzed against 5 L buffer A overnight using a Spectra Por membrane (Spectrum Labs, Rancho Dominguez, USA) with a molecular weight cut-off between 6 and 8 kDa. All samples were stored at -20°C .

Estimation of the NT*-Bri2 BRICHOS expression level and the yield after purification

To estimate the expression levels of NT*-Bri2 BRICHOS in the different cultures before harvest, a 100 μL sample (undiluted culture #1; threefold diluted culture #4; fivefold diluted culture #5; tenfold diluted culture #3, and #6–9; 20-fold diluted culture #10–11) was centrifuged to pellet the cells. The supernatant was discarded, and the pellet was re-suspended into 100 μL 8 M urea. 10 μL of each sample was loaded onto a 4–20% Mini-protean TGX stain-free precast SDS-PAGE gel (Bio-Rad, Munich, Germany). To estimate the amount of protein in the samples, already purified NT*-Bri2 BRICHOS was used as standard: 0.24, 0.48, 0.95, and 1.9 mg/ml unless noted otherwise. To create a standard curve, the standard bands were integrated with ImageLab software (Biorad, Munich, Germany), which correlated the band intensity to protein concentration.

The concentration of purified NT*-Bri2 BRICHOS was calculated using the protein specific extinction coefficient, $\text{Abs } 0.1\% (=1 \text{ g/L})=0.492$, after measuring the absorbance at 280 nm in triplicates. This method was also used to determine the concentration of the NT*-Bri2 BRICHOS standards used to estimate the expression level with SDS-PAGE.

The dry cell mass of culture #9–11 was determined by transferring 1 mL cell resuspensions (in triplicates), to already dried and weighed Eppendorf tubes. The cells were pelleted by centrifugation, the supernatant was removed, and the cell paste was dried at 65°C for at least 24 h until a stable weight was obtained. This method enabled an alternative way to estimate the expression level of culture #9–11, by determining the % of NT*-Bri2 BRICHOS relative to the total cellular proteins, using GelAnalyzer 19.1, and considering that the protein fraction of the total dry cell weight is 55% [30].

Isolation of the different oligomeric species using size exclusion chromatography

IMAC (immobilized metal affinity chromatography) purified NT*-Bri2 BRICHOS was concentrated to 3.4 mg/mL with a Vivaspin protein concentrator (10 kDa cut-off, GE Healthcare) at $4000\times g$ and 4°C . Then, the different rh NT*-Bri2 BRICHOS oligomeric species were isolated by size exclusion chromatography (SEC) using a Superdex 200 26/600 column (GE Healthcare, Uppsala, Sweden), which was equilibrated with Buffer B (20 mM NaP_i buffer pH 8.0 containing 0.2 mM EDTA), and an ÄKTA Explorer liquid chromatographic system (GE Healthcare, Uppsala, Sweden). The individual peaks corresponding to the differently sized oligomeric species were narrowly collected. Then, the rh NT*-Bri2 BRICHOS species were cleaved separately with 1: 600 thrombin (w/w, Merck) in a cold room overnight. After cleavage, the NT* tag was removed by reapplying the sample onto an IMAC column with buffer B (reverse IMAC), where rh Bri2 BRICHOS was found in the flow-through, and the NT*-tag bound to the column was eluted with buffer B containing 200 mM imidazol. To polish the Bri2 BRICHOS species, they were further purified with SEC one more time, using a Superdex 200 26/600 (for oligomer, tetramer, and dimer), or a Superdex 75 26/600 (for monomer) column (GE Healthcare, Uppsala, Sweden). The purified Bri2-BRICHOS species were stored at -20°C .

Citrate synthase thermal aggregation

The ability of the different rh Bri2 BRICHOS species to prevent non-fibrillar protein aggregation was assessed by suppressing thermo-denaturation of citrate synthase (CS). CS from porcine heart (Sigma-Aldrich, Germany) was diluted in 40 mM HEPES/KOH pH 7.5 to 600 nM and then incubated at 45°C with and without different concentrations of rh Bri2 BRICHOS oligomer or tetramer. The aggregation kinetics were monitored in triplicate using a microplate reader (FLUOStar Galaxy from BMG Labtech, Offenberg, Germany) by reading the apparent absorbance at 360 nm, as a measure of turbidity, under quiescent conditions.

A β 42 monomer preparation and Thioflavin T assay

A β 42 fused with a solubility tag (NT*) was expressed in BL21*(DE3) pLysS *E. coli* (B strain) cells (Novagen) and purified as described previously [23]. Briefly, NT*-A β 42 was purified by IMAC, and the NT* was released by TEV cleavage (1:100, w/w, in-house recombinantly prepared). The crude cleaved sample was lyophilized and re-dissolved in 20 mM Tris pH 8.0 containing 7 M Gdn-HCl. Pure A β 42 monomers were isolated with a Superdex 75 column (GE Healthcare, Uppsala, Sweden) using

a 20 mM sodium phosphate pH 8.0 buffer containing 0.2 mM EDTA. The A β 42 monomer concentration was calculated with a protein specific extinction coefficient of $1.424 \text{ M}^{-1} \text{ cm}^{-1}$ for (A $_{280}$ -A $_{300}$).

For testing the activities of rh Bri2 BRICHOS species against A β 42 fibril formation, 80 μL reaction solution containing 3 μM A β 42 monomers, 10 μM Thioflavin T (ThT) and different concentrations of Bri2 BRICHOS species at molar ratios 0, 10, 50, and 100% relative to A β 42 were added to each well of half-area 96-well microplates (Corning Glass 3881, USA). The fluorescence was recorded using a 440 nm excitation filter and a 480 nm emission filter (FLUOStar Galaxy from BMG Labtech, Offenberg, Germany) under quiescent conditions at 37 °C. Aggregation traces are averages of four replicates for all the experiments. For comparing the activities of each Bri2 BRICHOS species, the aggregation half time $\tau_{1/2}$ and the maximal growth rate r_{max} were extracted by an empirical sigmoidal Eq. (2) [25, 31]:

$$F = F_0 + A / (1 + \exp[r_{max}(\tau_{1/2} - t)]) \quad (2)$$

where A is the amplitude and F_0 the base value.

Stability of Bri2 BRICHOS oligomers and dimers

Rh Bri2 BRICHOS oligomers (10 μM) and monomers (5 μM) expressed in the bioreactor were incubated in 20 mM sodium phosphate pH 8.0 with 0.2 mM EDTA overnight at 37°C, and samples were analyzed by SDS-PAGE under native, reducing, and non-reducing conditions.


Results

Expression and purification of NT*-Bri2 BRICHOS in the bioreactor

A typical yield of NT*-Bri2 BRICHOS is 80 mg/L when purified with IMAC after expression in a shake flask type cultivation, using LB medium and inducing with 500 μM IPTG when the OD $_{600}$ is below 1. This is comparable to the yield of purified NT*-Bri2 BRICHOS produced by bioreactor culture #1, which essentially follows this simple shake flask expression protocol (a summary of all the essential parameters of each culture is summarized in Table 1). Notably, the same expression protocol, but using the richer TB medium doubled the yield to 180 mg/L (culture #2). Because we did not expect any significant improvement by optimizing the expression protocol using these complex media in terms of the cell density, we tested more sophisticated formulations, which included two semi-defined and one defined medium, originally described by da Silva, Korz, and Wyre (Culture #3, #4, and #5, respectively) [26–28]. Since native Bri2 BRICHOS has one disulfide bond and tends to form higher-order assemblies [25], we proceeded with a cultivation

strategy that minimizes the cellular stress level to maximize the expression levels [28, 32]. Thus, instead of fast growth at 37 °C before induction, we aimed to keep the temperature at a constant level of 25 °C throughout the entire cultivation. Furthermore, it is known that induction with high IPTG concentrations inhibits the exponential growth of *E. coli* [33], and therefore we induced with only 33 μM IPTG in the subsequent cultures.

Reaching OD $_{600}$ 1.2 after 17 h at 25 °C, cells cultivated in the defined medium suggested by Korz exhibited the slowest growth in direct comparison to the semi-defined formulations by Wyre and da Silva (OD $_{600}$ was 3.6 and 11.6, respectively). After a total culture time of 39 h, the da Silva-medium yielded an OD $_{600}$ of 120, Wyre-medium an OD $_{600}$ of 61, and Korz-medium an OD $_{600}$ of 50. Even though the medium according to da Silva yielded the best results in terms of cell density, after purification the yield was 0.6 g/L soluble NT*-Bri2 BRICHOS for Wyre and 0.5 g/L for da Silva medium (Table 1). This is an improvement of the NT*-Bri2 BRICHOS yield by a factor of two compared to the preceding cultivations. However, substantial impurities were seen for the NT*-Bri2 BRICHOS produced using the da Silva medium (Additional file 1: Figure S1). Nevertheless, we decided to express NT*-Bri2 BRICHOS one more time in medium from da Silva, due to its high potential for dense microbial growth. To test whether the expression level could be improved further, we induced with 50, 150, and 500 μM IPTG once OD $_{600}$ reached 30 (culture #6, #7, and #8, respectively). According to the OD $_{600}$ measured before culture harvest and the wet cell mass after harvest, there is a possible negative correlation between the amount of IPTG used to induce the culture and the final cell mass, however, the expression levels of NT*-Bri2 BRICHOS were comparable (Table 1). Induction with 150 μM IPTG resulted in an expression level of 7.9 g/L, whereas the expression levels of the cultures induced 50 μM and 500 μM IPTG were 7.9 and 6.2 g/L, respectively. Considering that the highest protein yield after purification (4.1 g/L) was achieved with the culture induced with 150 μM IPTG, we attempted to improve this further, by changing the point of induction. Repeating the protocol of culture #7 but inducing expression at OD $_{600}$ 60 instead of around 30 increased the expression level additionally by a factor of two to 18.8 g/L (culture #9, Fig. 1). Purification of NT*-Bri2 BRICHOS from this batch using IMAC yielded 6.4 g/L, which is the highest achieved in this study. Finally, to assess the reproducibility of this process, two more cultivations were performed replicating the conditions of culture #9. This time, the expression level was 10.3 g/L (culture #10) and 6.5 g/L (culture #11), which yielded 3.45 and 2.25 g/L of NT*-Bri2 BRICHOS after purification (Additional file 1: Table S1).




Isolation of monomer, dimer, and oligomeric species of NT*-Bri2 BRICHOS


NT*-Bri2 BRICHOS is prone to form different oligomeric species, that differ with respect to their potency to inhibit amyloid formation and non-fibrillar protein aggregation, respectively [25]. To enable a more precise investigation of NT*-Bri2 BRICHOS produced in the bioreactor, the protein was separated into monomers, dimers, and higher order oligomers with size exclusion chromatography (Fig. 2a). From this experiment interestingly four peaks were resolved, whereas three peaks are isolated from NT*-Bri2 BRICHOS expressed in shake flasks, corresponding to peaks I, III, and IV in Fig. 2a. The additional peak (II) corresponds to a tetramer (Fig. 3).

The individual NT*-Bri2 BRICHOS species were cleaved with thrombin and the rh Bri2 BRICHOS species were separated from the NT*-tag (containing a His₆-tag) by reverse IMAC. Finally, the rh Bri2 BRICHOS species were concentrated before isolation with SEC to obtain pure oligomeric, tetrameric, dimeric, and monomeric species (Fig. 2b, C) and their prolonged stability at 37 °C was confirmed (Additional file 1: Figure S4).

Inhibition of amyloid fibril formation and non-fibrillar protein aggregation

To assess if differences exist between rh Bri2 BRICHOS expressed in the shake flask or using a bioreactor, the inhibitory effect of rh Bri2 BRICHOS against






non-fibrillar aggregation of heated citrate synthase and amyloid fibril formation of A β 42 was tested. In the assay involving citrate synthase, rh Bri2 BRICHOS oligomers

showed a dose dependent activity against non-fibrillar protein aggregation and at a ratio of 1:2 (0.6 μ M citrate-synthase vs 1.2 μ M BRICHOS), the aggregation was completely inhibited (Fig. 4), similar to the capacity of the Bri2 BRICHOS oligomers produced in shake flasks [25]. The rh Bri2 BRICHOS tetramers did not show any inhibitory effects on thermo-induced citrate synthase aggregation, comparable to the lack of activity seen for monomer and dimer obtained from shake-flask expressed rh Bri2 BRICHOS [25]. These observations support that Bri2 BRICHOS large oligomers are required for general chaperone activity against amorphous protein aggregation.

Next, the activities of different species against A β 42 fibril formation were assessed using a ThT based assay. The different rh Bri2 BRICHOS species showed a dose-dependent influence on A β 42 fibrillation traces indicated by ThT fluorescence (Fig. 5). Among them, the dimer and tetramer were the most efficient species, in particular the dimer, as they showed the most prominent effect on increasing $\tau_{1/2}$ (time until half maximum fluorescence is reached) and decreasing r_{max} (the maximum growth rate) (Fig. 6). Further, the dimeric rh Bri2 BRICHOS lowered the final fluorescence intensity drastically, whereas the tetramer only showed minor effects on the final intensity at the highest concentration tested (Fig. 7). The effects on A β 42 fibril formation and final intensity for the tetramer may in part be due to the presence of dimers in the tetramer fraction. The oligomers and monomers did not reduce the final ThT intensity. Thus, according to the increase in $\tau_{1/2}$, the reduction of maximum rate and the final ThT intensity, the relative inhibition efficiencies against A β 42 fibril formation are dimer > tetramer > monomer > oligomer. Our previous data on the rh Bri2 BRICHOS species produced in shake flasks [25], in terms of






Fig. 5 Time dependent fluorescence traces of Thioflavin-T to test the inhibition efficiency of rh Bri2 BRICHOS monomers (a), dimers (b), tetramers (c), and higher order oligomers (d) against fibril formation of A β 42





Fig. 6 The aggregation half time $\tau_{1/2}$ (a) and the maximal growth rate r_{max} (b) of rh Bri2 BRICHOS species against A β 42 fibril formation

activity against A β 42 fibril formation, showed that the dimer had a $\tau_{1/2}$ of ~ 12 h, while ~ 10.5 h and ~ 5.5 h was achieved for the monomer and oligomer, respectively, giving the following efficiency order dimer > monomer > oligomer. Compared to the rh Bri2 BRICHOS species from shake flask cultures, the bioreactor produced

rh Bri2 BRICHOS species thus showed similar or better efficiency in inhibition of A β 42 fibril formation.

Discussion

To use recombinant proteins for medical or biotechnological applications, the production needs to be scalable and the typical expression levels need to be in



the high g/L scale to be economical [34, 35]. *E. coli* is a favorite workhorse for the production of biopharmaceuticals and is used for the production of about 30% of all clinically approved proteins [36], but a frequently occurring drawback of this heterologous host is the formation of inclusion bodies [28, 35, 37, 38]. To increase the yield and improve the solubility of otherwise aggregation prone peptides, the NT* domain was developed. NT* is a solubility tag that has successfully been used to increase the yield of several proteins up to a factor of eight, compared to other commonly used solubility tags [21, 23]. These results were obtained with shake flask cultivations using *E. coli*, hence the next logical step was to employ the NT*-domain for protein expression in a high-cell density bioreactor cultivation. In this study, we attempted to express and purify the rh Bri2 BRICHOS domain on a g/L scale employing the NT*-tag. Rh Bri2 BRICHOS has emerged as an interesting biopharmaceutical candidate for treating AD, as the domain is a potent inhibitor of Aβ42 amyloid fibril formation and in particular its associated neurotoxicity in vitro, in hippocampal slice preparations ex vivo, and

in *Drosophila* models in vivo [15]. In addition, rh Bri2 BRICHOS passes the blood-brain barrier [16].

To increase the expression yield of rh Bri2 BRICHOS compared to standard shake flask cultivations, we reasoned that the medium composition and feeding with a suitable carbon source are key elements to obtain a high cell density culture, in addition to proper oxygen supply and pH control. Accordingly, three previously suggested medium formulations that are supposed to support cell densities higher than 70 g/L (dry cell weight) were tested for culturing *E. coli* SHuffle cells in a bioreactor using a fed-batch setup [26–28]. Interestingly, this initial experiment revealed that an OD₆₀₀ above 100 was only obtained for the medium formulation described by da Silva et al., why we chose this medium for all subsequent cultivations.

Furthermore, the influence of different IPTG concentrations for induction on the cell density at harvest and the expression level was tested (Table 1, culture #3, 6, 7, and 8). We observed a fourfold increase in expression level as the IPTG concentration was increased from 33 to 50 μM, however, the cell density at harvest was severely decreased if the IPTG concentration was 150 μM or

higher, but without elevating the expression level. This confirms the importance of reducing and optimizing the inducer concentrations, to minimize cellular stress factors, as previously suggested for improved expression levels of soluble protein [28, 32]. Induction with 150 μ M IPTG at OD₆₀₀ of 30 resulted in an NT*-Bri2 BRICHOS expression level of 7.9 g/L. A minimal adjustment of this protocol by inducing protein expression at OD₆₀₀ of 60 instead, elevated the expression level to 18.8 g/L (15.2 g/L if estimated from the dry cell weight), which competes with the highest reported recombinant protein expression levels for *E. coli* (Table 2) [26, 28, 37–44]. The caveat with this protocol is the high batch-to-batch variation, as repeating the exact cultivation conditions of #9 (culture #10 and #11) has not consistently resulted in expression levels of > 15 g/L. Nevertheless, at least 6 g/L NT*-Bri2 BRICHOS can be expected (Additional file 1: Table S1).

Purification of Bri2-BRICHOS was executed in the same manner as previously described [25], and involved isolation of NT*-Bri2 BRICHOS with IMAC. The highest obtained yield after purification was 6.7 g/L (culture #9), which corresponds to 34% of the expressed protein. The main problem we faced during purification was that a large portion of NT*-Bri2 BRICHOS was found in the pellet after cell lysis/centrifugation and that the protein did not fully bind to the column and was to a large extent present in the flow-through (Fig. 1c). Therefore, the flow-through was reapplied to increase the yield, but still, a significant fraction was not recovered, which means

that the yield most likely can be improved by additional optimizations.

Another relevant question that we wanted to investigate was whether the protein aggregation inhibition profiles of bioreactor produced rh Bri2 BRICHOS are comparable to previously published data for the shake flask-produced protein. To answer this, after removal of the NT*-tag with thrombin, rh Bri2 BRICHOS was separated into the individual oligomeric species using SEC. Interestingly, we were not only able to isolate monomers, dimers, and higher order oligomers but also tetramers, a species that we were not able to purify from our previous shake-flask preparations. The tetramer was predominantly formed after the removal of NT* from the NT*-Bri2 BRICHOS dimer. So far, we do not know what can trigger the transformation of the tetramer from the dimer, but the high concentration is probably an explanation as the Bri2 BRICHOS oligomerization process is sensitive to increased concentration [31]. Also, we cannot exclude the possibility that the composition of the cultivation medium, e.g. metals, could have potential effects on the equilibrium of the different species, and future work is necessary to elucidate the exact mechanisms behind this behavior. Nevertheless, in accordance with earlier results, CS aggregation was only inhibited by the presence of Bri2 BRICHOS oligomers. Likewise, the inhibition profile of Bri2 BRICHOS against A β 42 amyloid formation is comparable, suggesting that the chaperoning capacities against fibrillar amyloid aggregation and non-fibrillar

Table 2 Summary of some of the highest reported expression levels of recombinant protein using *E. coli*

Protein	Molecular Weight (kDa)	Expression level (g/L)	Yield after purification (g/L)	Solubility ^a	References
surface protein A from <i>Erysipelothrix rhusiopathiae</i>	42	6.4	n.r	n. r	da Silva et al. [26]
tilapia insulin-like growth factor-2	7	9.7	1.99 ^e	5 M urea (IB)	Hu et al. [37]
human soluble B lymphocyte stimulator	18	3.8	n. r	n. r	Zhang et al. [39]
model cytoplasmic protein ^b	n. r	17.6 ^c	n.r	0.1 M Tris-HCl	Kopp et al. [40]
chemotaxis protein CheY fused to green fluorescent protein from <i>Aequorea victoria</i>	n.r	12.0 ^d	n.r	Bug Buster reagent	Wyre et al. [28]
human leptin	16	9.7	3.98 ^e	8 M urea (IB)	Jeong et al. [41]
human interleukin 6	n.r	8.5	n.r	n. r	Tae et al. [38]
phenylalanine dehydrogenase mutant from <i>Trametes chromis intermedium</i>	40	n.r	4.6	20 mM KP _i	Zhao et al. [42]
NT*-Bri2 BRICHOS	29.6	18.8	6.5	20 mM Tris- HCl	This study

n.r. – not reported. IB – inclusion bodies

^a Refers to the buffer used to recover the proteins after cell lysis

^b The exact identity of the model cytoplasmic protein is not reported

^c Kopp et al. describe a repetitive fed-batch protocol, in which the expression level is increased after every round. The value here represents the expression level after the first round of fed-batch to make it comparable to the other values reported here. The highest expression level that Kopp et al. reported was 35.5 g/L

^d Highest expression level reported. The highest concentration of soluble protein in the same study was 6 g/L

^e Estimated from the reported % recovery after purification

amorphous aggregation of Bri2 BRICHOS are independent of the expression and purification protocol.

Conclusion

In this study, we establish an expression protocol of the human small heat shock protein chaperone domain Bri2 BRICHOS. Optimization of the process resulted in an expression level of up to 18.8 g/L, which is among the highest protein expression levels reported for *E. coli*. The high yield is likely attributed to the use of the NT*-tag, which drastically increases the solubility and expression levels of certain peptides and proteins. Since rh Bri2 BRICHOS is a promising candidate for treating AD, the protocol described in this paper is important to enable future research and successful translation into clinical trials.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12934-021-01638-8>.

Additional file 1. Table S1. Summary of key parameters for the expression and purification of NT*-Bri2 BRICHOS. **Figure S1.** SDS PAGE of NT*-Bri2 BRICHOS IMAC eluates. **Figure S2-3.** Estimation of the NT*-Bri2 BRICHOS expression level using SDS-PAGE. **Figure S4.** Native PAGE and SDS-PAGE of rh Bri2 BRICHOS.

Acknowledgements

The authors thank Mats Sandgren, who provided the bioreactor infrastructure located at the Biocentrum, Swedish agricultural University, Uppsala, Sweden.

Authors' contributions

BS, GC, NK, AR, and JJ, were responsible for conceptualization and choosing the methodology. BS and JP performed the bioreactor experiments and analyzed and interpreted the data. GC performed the protein aggregation inhibition assays and analyzed and interpreted the data. JP tested the stability of the Bri2 BRICHOS oligomers and monomers. BS, GC, and JJ were major contributors in writing the manuscript. NK, AR, and JJ were responsible for supervision, validating and analyzing the data, and reviewing and editing the manuscript. All authors read and approved the final manuscript.

Funding

Open access funding provided by Karolinska Institutet. This work was supported by the Swedish Research Council (2020-02434), the Center for Innovative Medicine (CIMED) at Karolinska Institutet and Stockholm City Council (613/06), and the Swedish Brain Foundation (FO2018-0312). G.C. is supported by the Olle Engqvists Stiftelse (192-522), Swedish Alzheimer foundation (AF-836251), Åhlén-stiftelsen (mC9h18), and the Petrus and Augusta Hedlunds Stiftelse (M-2018-0998).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Author details

¹Department of Biosciences and Nutrition, Karolinska Institutet, Neo, 141 86 Huddinge, Sweden. ²Department of Anatomy, Physiology, and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden.

Received: 4 May 2021 Accepted: 16 July 2021

Published online: 30 July 2021

References

- Dobson CM. Protein folding and misfolding. *Nature*. 2003;426:884–90.
- Ankarcrona M, Winblad B, Monteiro C, Fearn C, Powers ET, Johansson J, et al. Current and future treatment of amyloid diseases. *J Intern Med*. 2016;280:177–202.
- Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. *Lancet Neurol*. 2016;15:455–532.
- Goldschmidt L, Teng PK, Riek R, Eisenberg D. Identifying the amyloids, proteins capable of forming amyloid-like fibrils. *Proc Natl Acad Sci USA*. 2010;107:3487–92.
- Johansson H, Nerelius C, Nordling K, Johansson J. Preventing amyloid formation by catching unfolded transmembrane segments. *J Mol Biol*. 2009;389:227–9.
- Willander H, Askarieh G, Landreh M, Westermark P, Nordling K, Keränen H, et al. High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C. *Proc Natl Acad Sci USA*. 2012;109:2325–9.
- Nerelius C, Gustafsson M, Nordling K, Larsson A, Johansson J. Anti-amyloid activity of the C-terminal domain of proSP-C against amyloid β -peptide and medin. *Biochemistry*. 2009;48:3778–86.
- Vidal R, Frangione B, Rostagno A, Mead S, Révész T, Plant G, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. *Nature*. 1999;399:776–81.
- Vidal R, Révész T, Rostagno A, Kim E, Holton JL, Bek T, et al. A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. *Proc Natl Acad Sci U S A*. 2000;97:4920–5.
- Oskarsson ME, Hermansson E, Wang Y, Welsh N, Presto J, Johansson J, et al. BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cells. *Proc Natl Acad Sci U S A*. 2018;115:E2752–61.
- Willander H, Presto J, Askarieh G, Biverstål H, Frohm B, Knight SD, et al. BRICHOS domains efficiently delay fibrillation of amyloid β -peptide. *J Biol Chem*. 2012;287:31608–17.
- Cohen SA, Arosio P, Presto J, Kurudenkandy FR, Biverstål H, Dolfe L, et al. A molecular chaperone breaks the catalytic cycle that generates toxic A β oligomers. *Nat Struct Mol Biol*. 2015;22:207–13.
- Hermansson E, Schultz S, Crowther D, Linse S, Winblad B, Westermark G, et al. The chaperone domain BRICHOS prevents CNS toxicity of amyloid- β peptide in *Drosophila melanogaster*. *DMM Dis Model Mech*. 2014;7:659–65.
- Kurudenkandy FR, Zilberter M, Biverstål H, Presto J, Honcharenko D, Strömberg R, et al. Amyloid- β -induced action potential desynchronization and degradation of hippocampal gamma oscillations is prevented by interference with peptide conformation change and aggregation. *J Neurosci*. 2014;34:11416–25.
- Poska H, Haslbeck M, Kurudenkandy FR, Hermansson E, Chen G, Kostallas G, et al. Dementia-related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits A β 42 toxicity in *Drosophila*. *Biochem J*. 2016;473:3683–704.
- Tambaro S, Galan-Acosta L, Leppert A, Chen G, Biverstål H, Presto J, et al. Blood-brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice. *J Biol Chem*. 2019;294:2606–15.
- Galan-Acosta L, Sierra C, Leppert A, Pouliopoulos AN, Kwon N, Noel RL, et al. Recombinant BRICHOS chaperone domains delivered to mouse brain parenchyma by focused ultrasound and microbubbles are

- internalized by hippocampal and cortical neurons. *Mol Cell Neurosci*. 2020;105:1033498.
18. Johansson H, Nordling K, Weaver TE, Johansson J. The Brichos domain-containing C-terminal part of pro-surfactant protein C binds to an unfolded poly-Val transmembrane segment. *J Biol Chem*. 2006;281:21032–9.
 19. Rising A, Johansson J. Toward spinning artificial spider silk. *Nat Chem Biol*. 2015;11:309–15.
 20. Askarieh G, Hedhammar M, Nordling K, Saenz A, Casals C, Rising A, et al. Self-assembly of spider silk proteins is controlled by a pH-sensitive relay. *Nature*. 2010;465:236–8.
 21. Kronqvist N, Sarr M, Lindqvist A, Nordling K, Otkovs M, Venturi L, et al. Efficient protein production inspired by how spiders make silk. *Nat Commun*. 2017;8:45.
 22. Sarr M, Kronqvist N, Chen G, Aleksis R, Purhonen P, Hebert H, et al. A spider-derived solubility tag enables controlled aggregation of a designed amyloid protein. *FEBS J*. 2018;285:1873–85.
 23. Abelein A, Chen G, Kitoka K, Aleksis R, Oleskovs F, Sarr M, et al. High-yield production of amyloid- β peptide enabled by a customized spider silk domain. *Sci Rep*. 2020;10:225.
 24. Abdelkader EH, Otting G. NT*-HRV3CP: An optimized construct of human rhinovirus 14 3C protease for high-yield expression and fast affinity-tag cleavage. *J Biotechnol*. 2021;5:751.
 25. Chen G, Abelein A, Nilsson HE, Leppert A, Andrade-Talavera Y, Tambaro S, et al. Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state. *Nat Commun*. 2017;8:55.
 26. da Silva AJ, Horta ACL, Velez AM, lemma MRC, Sargo CR, Giordano RLC, et al. Non-conventional induction strategies for production of subunit swine erysipelas vaccine antigen in *E. coli* fed-batch cultures. *Springerplus*. 2013;2:1–12.
 27. Korz DJ, Rinas U, Hellmuth K, Sanders EA, Deckwer WD. Simple fed-batch technique for high cell density cultivation of *Escherichia coli*. *J Biotechnol*. 1995;39:59–65.
 28. Wyre C, Overton TW. Use of a stress-minimisation paradigm in high cell density fed-batch *Escherichia coli* fermentations to optimise recombinant protein production. *J Ind Microbiol Biotechnol*. 2014;41:1391–404.
 29. Strandberg L. The use of fed batch cultivation for achieving high cell densities in the production of a recombinant protein in *Escherichia coli*. *FEMS Microbiol Rev*. 1994;14:53–6.
 30. Ingraham JL, Neidhardt FC, Ingraham JL, Low BK, Curtiss R III, Magasanik B. *Escherichia coli* and *Salmonella typhimurium*: cellular and molecular biology. New York: ASM press; 1987.
 31. Chen G, Andrade-Talavera Y, Tambaro S, Leppert A, Nilsson HE, Zhong X, et al. Augmentation of Bri2 molecular chaperone activity against amyloid- β reduces neurotoxicity in mouse hippocampus in vitro. *Commun Biol*. 2020;3:87.
 32. Hsu CC, Thomas ORT, Overton TW. Periplasmic expression in and release of Fab fragments from *Escherichia coli* using stress minimization. *J Chem Technol Biotechnol*. 2016;91:815–22.
 33. Dvorak P, Chrast L, Nikel PI, Fedr R, Soucek K, Sedlackova M, et al. Exacerbation of substrate toxicity by IPTG in *Escherichia coli* BL21(DE3) carrying a synthetic metabolic pathway. *Microb Cell Fact*. 2015;14:201.
 34. Tripathi NK, Shrivastava A. Recent developments in bioprocessing of recombinant proteins: expression hosts and process development. *Front Bioeng Biotechnol*. 2019;7:21.
 35. Ferreira RDG, Azzoni AR, Freitas S. Techno-economic analysis of the industrial production of a low-cost enzyme using *E. coli*: the case of recombinant β -glucosidase. *Biotechnol Biofuels*. 2018;11:78.
 36. Huang CJ, Lin H, Yang X. Industrial production of recombinant therapeutics in *Escherichia coli* and its recent advancements. *J Ind Microbiol Biotechnol*. 2012;39:383–99.
 37. Hu SY, Wu JL, Huang JH. Production of tilapia insulin-like growth factor-2 in high cell density cultures of recombinant *Escherichia coli*. *J Biotechnol*. 2004;107:161–71.
 38. Tae WK, Bong HC, Yong KC. Production of soluble human interleukin-6 in cytoplasm by fed-batch culture of recombinant *E. coli*. *Biotechnol Prog*. 2005;21:524–31.
 39. Li Z, Zhang X, Tan T. Lactose-induced production of human soluble B lymphocyte stimulator (hsBLyS) in *E. coli* with different culture strategies. *Biotechnol Lett*. 2006;28:477–83.
 40. Kopp J, Kittler S, Slouka C, Herwig C, Spadiut O, Wurm DJ. Repetitive fed-batch: a promising process mode for biomanufacturing with *E. coli*. *Front Bioeng Biotechnol*. 2020;8:94.
 41. Jeong KJ, Lee SY. High-level production of human leptin by fed-batch cultivation of recombinant *Escherichia coli* and its purification. *Appl Environ Microbiol*. 1999;65:3027–32.
 42. Zhao C, Wang L, Li D, Li J, Ge Y, Liang T, et al. High-cell-density fermentation of *Escherichia coli* for expression of a recombinant phenylalanine dehydrogenase mutant and its purification. *J Chem Technol Biotechnol*. 2021;96:199–206.
 43. Merlin M, Gecchele E, Capaldi S, Pezzotti M, Avesani L. Comparative evaluation of recombinant protein production in different biofactories: the green perspective. *Biomed Res Int*. 2014;5:468.
 44. Choi JH, Keum KC, Lee SY. Production of recombinant proteins by high cell density culture of *Escherichia coli*. *Chem Eng Sci*. 2006;61:876–85.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

